CRBP - Earnings call transcript Q4 2019 | Corbus Pharmaceuticals Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the Corbus Pharmaceuticals Fourth Quarter and Year End December 31st, 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Ted Jenkins, Senior Director of Investor Relations and Corporate Communications. sir. ahead, go Please

Ted Jenkins

for morning, listeners this this that intentions, and or state Good statements are to involve and call I’d remind management’s risks projections expectations beliefs, our remarks hopes, future. everyone. you. These time, forward-looking At uncertainties. like may the Thank made during

Corbus’ made could Forward-looking securities statements forward-looking laws. are the current and Harbor results pursuant on actual expectations, on materially. statements call provisions Safe differ The are to this of federal based the

undue place not on should any you result, a statements. reliance forward-looking As

factors of Securities of to These the Commission. the Some company’s the Exchange are such cause differ with materially that on Exchange section We website. Commission’s in the could forward-looking documents to website, and actual are from encourage periodic discussed and by files carefully. you and results reports available Corbus those the documents review in contemplated Securities investor statements these the

today Executive and White, Yuval and Joining Dr. Cohen, Chief the on Craig of Millian, Research; Chief Head Chief call our Chief Sean Moran, our our Financial me Officer. our Barbara Officer; are Medical Dr. Commercial Officer; Officer

With to is my call the to it turn Yuval. that, over pleasure

Yuval Cohen

drug Overall, Ted. targeting multiple important this thank us and Thank call realizing development system. morning, our marked towards clinical progress the was you joining in this the become for Good you, and leader everyone corporate An morning. XXXX by on achievements. to vision endocannabinoid

in of dermatomyositis. lenabasum the favorable and the College continued extension for at We durable that two-year label presentations of open for our Rheumatology Annual and presented X data Meeting, safety study sclerosis, new including data, we study outcomes Phase American XXXX systemic where introduced oral our showed

top systemic and data completed this our summer. for Phase we our Xb study coming well positioning sclerosis RESOLVE X, Phase addition, enrollment both fibrosis cystic In line study us in in X

potential to our the like endocannabinoid provide and body’s diseases. fibrotic We the a treat to known ECS, system, that as also all therapies remind you company. as inflammatory, I’d targeting holds to metabolic vision of believe the new

that We modulate are medicines focused system. biological powerful novel this on developing potential

chemistry, and biology, on track regulatory deep have development strategy, record expertise well in medicinal a We as endocannabinoid proven plan. of executing our as system clinical patent

we’ve the important expertise focusing laying necessary the past to commercial on year, successful having product for execute groundwork been also a This launch.

As our look Phase fibrosis. track our X we this ahead the top to to systemic summer, Phase we line of in study sclerosis year, study for Xb cystic from followed are by this stage be lenabasum data on

study Lupus expect Health. data of also study X Erythematosus We in lenabasum the by XXX part this of Phase line and in Systemic top the is Institutes patient of latter National That from our run funded year.

Phase look will we and Finally, forward of launch that study expect X to to CRB-XXXX generate. data safety study year key the our this

to mitigation studies. say risk have clinical our Like experiencing chain the few we’re with the coronavirus of trials, comments in White evolving clinical to on words our many plan want not do impact business our a supply workforce of peers, Dr. are this provides and from to how or delays coronavirus on Before situation. a dealing I present, or programs, we At COVID-XX significant rapidly and the robust possible on place deal effects we our operations. research ensure or with put short and safety situation

and and health federal are local We following from situation monitoring carefully the guidance authorities. are

Head to call on White, research our Dr. the to over of Officer Barbara provide Chief quick With I’d that, like and clinical programs. you update with a Research, our and Medical to turn

Barbara White

data human demonstrated and studies Phase efficacy molecule sclerosis, that initial is oral, Lenabasum have a systemic X and models, safety, of in an to fibrosis been variety has been in small Yuval. biomarker Thank cystic CBX inflammation and you, and in reduce shown agonist fibrosis dermatomyositis preclinical promising patients. our

ACR sclerosis or efficacy or lenabasum Meeting after maximum score X cutaneous ACR safety Rheumatology OLE and American we Annual Modified above CRISS systemic reached index from to acceptable of about Skin XX in in were ACR dosing data the continued chronic out November at the remained with an score Phase data presented. College X.XX Improvement XXXX, baseline profile time The the Rodnan Score or that of have diffuse at in points response of X months the showed minus X. presented At treatment. the combined median of

of expected of Top study this fully dosed. treatment systemic Our is on Phase lenabasum schedule data for sclerosis and summer. XXX subjects X XX-month global RESOLVE enrolled X with line the are

subjects learn that pleased X be part controlled X Phase enrolled eligible the RESOLVE open label in the the You double-blind, XX% the have completed study of to who extension. will of randomized, placebo to-date

the We sclerosis. treatment underlying and for that mechanisms life-threatening on optimism optimistic in show Phase top safety X of remain disease is will favorable the benefits line the lenabasum biologic upcoming this data and activities systemic between This based in disease. lenabasum positive consistency rare,

primary efficacy baseline authorities If and are Asia, X biomarker about safety, we in the for X disease similarities the efficacy US, Phase use data same studies. marketing X subjects acceptable, remains encouraging the positive to discussions plan safety profile characteristics authorizations. Phase in endpoint, hold RESOLVE difficulty] with of CRISS filing and Europe Phase ACR and X and the the regulatory X [technical in Phase the between Our and data, X score and

Phase treatment study global for dermatomyositis. is Our of the DETERMINE study second lenabasum X of

in later of year, expecting label open be We already this this fully the is rate study of enrollment are extension pleased study to very completion with with XXXX. The enrolled active.

supportive positive of sclerosis. X reasons Phase that We systemic study are similar show optimistic and the for will safety data efficacy DETERMINE

Meeting oral Annual chronic of with safety continued in at with the subjects months. and dermatomyositis November acceptable ACR lenabasum an through in XXXX dosing XX Data presentation highlighted

a of the minus that in subjects OLE Activity the in open in baseline mean XX months. seen points was time. remained study improvement Severity with CDASI, enrolled Continued Phase at Dermatomyositis improvement active or the disease score from activity at XX X this XX of Index label XX.X Cutaneous extension and skin in

fibrosis, expected believe exacerbations November. mutation last data represents to XX-week of Xb X people symptoms, lung worsening new with option of signs fibrosis. cystic Pulmonary at for lung a CF in and the worsening a function. exacerbations lenabasum potential often including study. manifestations CF background Without in current Phase in significant XXX for events from cystic lenabasum study enrollment We exacerbations CFTR study patients with of CF anti-inflammatory in Top respiratory RESOLVE reducing therapy. completed increased regard rates to our recurrent are inflammation, clinical acute pulmonary high risk Turning of our are following line or pulmonary

sensitivity, to effects. designed metabolism, avoid to minimal with glucose these potentially CBX in access has literature, a effects order animal body to lipid demonstrated metabolic have of beneficial the agonist fat and brain supporting hepatic is CRB-XXXX, asset, tolerance, second disease models robust Our psychiatric seen fat on in CRB-XXXX inverse with effects insulin rimonabant.

on have assays. beneficial effects inflammation in potential additional and We identified fibrosis

colleagues Dr. [Tan] last [ph] with month CRB-XXXX and reported block fibrosis. liver

are treatment potential scan significant will X CRB-XXXX study study of CRB-XXXX to the pharmacokinetics fibrosis also a tolerability be therapeutic as lead considering will QX to to diseases Phase whether finding We will brain. NASH that potential a the CBX of to testing CRB-XXXX. PET evaluate and plan include exposures safety, used to in X plan our We such in test the other for as CRB-XXXX CRB-XXXX diabetic in with to We Phase with start neuropathy.

candidate specialists, our anticipates representing growing year, our of our DMPK medicinal selection Lastly, output of research team this modulators and of research next biologists. compound team the chemists, toxicologists,

now turn Yuval. I’d the to call back

Yuval Cohen

lenabasum approval to we Barbara. for In you, of launch. potential XXXX, prepare and began the its commercial Thank subsequently

our of are progress the educational systemic We in last with very making initiatives, initiation sclerosis good disease including campaign our week.

like activities. you update now turn Craig to our commercial call would Chief over Officer, to I Commercial who’ll Millian, on the provide an our

Craig Millian

success. and On at morning, focused in critical I highlighted elements our three Yuval prelaunch good to planning, you, everyone. Thank call, on this point we’re last that ensure

our commercial building leadership team capabilities. and First,

market foundation and ahead strong establishing communicating regulatory that provides approval. compelling third, Second, a a narrative scientific context an insights a potential deep appropriate of of

leaders market have affairs, leads and access, of a drive chain, at a supply advocacy. analytics our patient medical talented team, successful commercial established relations building with we including and group marketing, Starting public for launch, capable operations, to

systemic of recent most investor both have US patients, in Corbus Many and in develop the of to strong on our both fibrosis cystic a payers and continue these market deck and Europe. physicians in with We the into foundation and research sclerosis conducted incorporated market insights available insights been have website.

with Now is sclerosis. have is impact considerable scleroderma some to disease I’d managing like highlight of active once on in unmet or moment diffuse lives often need to early our to diagnosed profound. a of These and the systemic their patients specific take patients The learnings their key greatest sclerosis. challenges systemic

than fewer believe also can reach outreach. community centers majority patients. with there by small are centers perspective, From customer-facing of excellence, estimate multichannel a these roughly FDA go-to the we rheumatologists and of prescribers in scleroderma that augmented we we a potential approval, targeted XX team Upon and at the treat scleroderma efficiently market X,XXX

disease have immunosuppression. who address scleroderma treatment available generally and to but or underlying used best single with added Currently progression, Rheumatologists symptoms they disease. come they patients no of manage complications, but the can specific of do treatments, approved the with address the not burden totality the organ therapies

rheumatologists payers research payers met and X treatment and market unmet also current of profile is the research, potential treatments, disease the data, we’ve study X in with access our in that need Payers product with market Phase limitations Phase with as target systemic appreciate sclerosis lenabasum well for our a blinded payers. options. need, Most our US receptive recognizing interest and rare This In recently, both Europe. to substantial of by highly completed on are the from positive profile value a was patients, based tested as we design. new

overall for burden how of treatments, access with diseases. serious reimbursement payers profile lack product consistent we on decisions. treatments as explored and for might potential approach value in acknowledged Based rare potential disease a presenting the being other After of lenabasum lenabasum, payers approved

post-data more to pricing course, done strategy. will before establish Of finalizing be our value work platform

like to Finally, on the call is recently literature. with to This before market systemic scientific I’d course, you KOL of insights, advisors, and our our sclerosis conversations that back launched based update disease targets campaign rheumatologists. on turning the campaign Yuval, education

behind evaluate devastating sclerosis. systemic The The sclerosis campaign fibrosis. the campaign calls totality for inflammation that both is a healthcare of professionals and by to the insight disease driven is systemic complex,

agents anti-fibrotic complications. symptoms immunosuppressive address current using or or However, organ specific only approaches

the learn systemic encourage totalssc.com, and was to novel totalssc.com visit the emphasizes you the including last feature A also considers campaign website that of week unravels of is systemic to and risk burden also campaign sclerosis patient, potential a the the This website This the mortality more. launched mechanisms, CBX receptor. targeting on including and of sclerosis increased of I disability. complexity central total

medical relevant websites, we In aimed the the paid search campaign, coming weeks, at will the reaching ads all full and including social on audience. launch and rheumatology media

In and to initial we reach. campaign be upcoming addition, our Congresses. at will is add This Medical plan expand throughout to content highlighted XXXX, the and investment our step increase

strong In are around summary, progress fundamentals. focused providing forward toward ensuring we capabilities we as to execution commercial We advance launch. our on updates future and pre-launch look

back financial Yuval the to for turn call me the Let discussion.

Yuval Cohen

a million in a gross position. Thank I’d like our February $XX past you, sheet. to raised over the has balance its bringing we months Craig. million. In provide proceeds brief XX from Corbus financial offering, update $XX last month, public strengthened total on capital the to raised

$X.X payments on together public Foundation $XX the remaining net XXst, of December XXXX, to quarter offering in operations hand as XXXX. $XX we fourth We cash the and into milestone expect Cystic million of million Fibrosis million of fund Award just the from the the from did, proceeds in with the

important want look I and that could multiple our yield closing, diseases. the improve to data that to target compound system This In vision with that transformative year, on We of key our the it will focusing forward what most be treatment our of inflammatory endocannabinoid to brings. highlight has medicines again, readouts the potential novel fibrotic year-to-date.

our it like and With today. time that, to over any thank questions the attention, all I’d and listeners for from to for your you turn operator

Operator

be now session. Thank question-and-answer Thank [Operator At we’ll conducting Instructions] this you. time, you. a

RBC with with Markets. your from Our line Abrahams questions. Capital is first Please of question the proceed Brian

Brian Abrahams

are as the key my Hi, into Is much trial. lot the as open And closer your the questions. and had that there? in from might Phase Thanks we both look sounds readout? I it like first guess extension. a I retention what’s patients a the get are like regulatory as to subcomponents label clinical perspectives? be important the How for X? And potential high the there. guys follow-up. taking X It of conduct systemic feeling the senses then you What’s on CRISS Phase overall also to about so sclerosis rolling off the

Barbara White

remember Thanks, to Brian. those. I’ll try all of

trial the how’s First, Great. going?

really end. of subjects know, reaching, are of Most study. subjects two the this in thirds we’re out the study you on of XX, month this of are the out of finish now, closing near XX We’re the so the

conduct. been the far, with we’ve subjects. the pleased and with And pleased So we’ve especially patients the enthusiasm the been of

And the that terms you as not see more in delighted. open of if so. retention And can could year maybe part I we’ve think into we that, some of have label, we in of think be eligible XXX XX% it And know, of or I got you over XX%, people we in rolling know, the X% the label, for and have, a – you dropout been we’ve now. think, them had, in open I over

to retention really is – rate it’s to in data, and going it’s is that the to-date going patients long-term to So safety single approvability give on rate us safety the great because quite also important, the important provide not on outcomes. information, great. quite To-date have study good, again, even other trial data. additional retention it’s a much help based is we’re but more in support additional acceptable been this safety to one. the is enrollment only will we that OLEs And the think help rate And this

the The disease. all that tool us CRISS of at across ACR We address globe regulators to think the components will the of gives of the totality look a the the ACR CRISS.

is It the Just what regulatory better overall is of measure was out so not, is important. a patients’ or Craig a it and outcome. pointed

to improvement function, of patients in the individual think all thickening, lung the we terms as We improved in or do expect important do are what global, that. what’s change components them, change will well mRSS has regulators and think patients. physician that will certainly to each or thinks, they In all interested of think of So of we in variety and skin the in the function support not? as to analysis change pay to in patient patient we them the attention a be

Brian Abrahams

that maybe some guess, the Thanks in talked lenabasum research about done that rare so sclerosis. a diseases. interesting of initial question consistent findings help from with of to then treatments about for Craig, market as for I how and if of And for wondering thinking they’re of much, the Barbara. you’ve obviously, you types a the systemic And your just some jump work bit before And consistent and it’s just was back viewing, potential treatments queue. the you pricing the know, it but value certain us are payers as I of understand the you I’ll to specifically, with premature expressing being and framework value? Thanks. for in some viewing label, mention were talk it’s, little the other data about value maybe payers a provide sort more did in that you access receptivity specific

Craig Millian

Yeah.

Brian. So thanks the question, for

engaged much early. it is a very are pricing we obviously know, with and You strategy

into to terms general you that, that numbers, research conducted. to I appreciate some you of going thoughts not be but know, specific share in happy the get I’d I’m know, So, we’d

studied. our as focusing serious know, in emphasis and well our is value is scleroderma with which which disease, systemic form on diffuse drugs the we’re been You first patients on proposition the most as optimizing as in you’re the of population aware, sclerosis

in rare is of concept of patient prevalence category, the within – category. the And population heard systemic I the obviously of a X that per So falls disease about term US diffuse I’ve the but not sclerosis clearly this disease this disease that ultra-rare, rare diffuse medium new used. the patients is kind and XXX,XXX and

a when would access levels I’ll throughout bit reaction systemic ClearView systemic were agreed be conducted the was a pricing aware options, that research And, specific independently know, this with there the sclerosis payers rare leave a you that based suggested by considering there is Our quite profile, Consulting. for you serious limited broad thought, flexibility of product And the overall. treatments no treatment that on payers disease market range. lenabasum of with they’re to that sclerosis blinded indicated

as per with SSC. other about And their similar it with analogues prevalence rates And XX be diffuse consistent is say per and overall XXX,XXX XXX,XXX. to again, I’d from diseases X is SSC serious would treatment again, thought

So, and in course, you dry and know, cut you’re not of terms it’s at access this as point, levels. aware, of

So depending strategy, access pricing levels are on you and of know, different achieved. reimbursement

certainly the these a research. we you plan insights we lot on, the goals So leverage set. of But in that payer depends to know,

We’re just in our value mentioned, proposition, those insights combine of really but we’ll beginning work determine we health certainly with optimal final know, pricing modeling our our road strategy. have and further data we label, health economic economic can’t an we’ll determine until final the you as you a and down our value terms modeling,

Brian Abrahams

Great, so thank much. you

Operator

from The proceed questions. Raycroft next Please Maury line question is of the coming with Jefferies. with your

Maury Raycroft

and start are for morning, everyone on from blood my biomarkers blood those samples questions. samples? the good blinded of trials, patients you on on Hi, regular late-stage a inflammatory basis? for or and sclerosis, fibrosis the you’re taking other for any your can systemic seeing what thanks possibly And To taking in qualitatively comment you or assessing

Barbara White

samples that So, from first involved of taking we tissue. we’re are them actually all, taking

in group the markers why little common immunosuppressives, you study the background immunosuppressives involved are elevated, that probably of at not subjects, least some relevant. because So know, tissues. That’s on fact, biomarkers was these in are them in less to that and blood. background XX% in looking of at elevated we’re of about it’s or so many found find a more in We patients that’s informative, Phase we think the our X as that quite

and the patients histology inflammation of certainly we with markers expression cells we in of dermatomyositis. patients the sputum of looking are sclerosis with systemic and will And skin So gene look CF. in at and at

recall, same the As data cells the in skin, you and mediators inflammatory CF we encouraging saw may scleroderma reduction in the Phase in in skin inflammation of fibrosis and and study samples in reduction and skin. with Maury, very mediators a in the certainly inflammatory cells reduction a the X DM of

Maury Raycroft

Got are samples? it. And guess, that getting a serial are points you time? those you’re over time I there the different taking on basis

Barbara White

some of than You we’re just XX know, to often little volunteer may more their them at in doing it’s know, think in study, the easier because DM by months, CF frequently. Maury, the being three, we’re study. not patients the I doing the are except they’re baseline of that come so done you mostly but The for the end and beginning more the biopsies, a

Maury Raycroft

it, safety okay. SAD/MAD Got some And okay in XXXX, individuals clarifying, then and will And obese just include PK study? initial your you –

Barbara White

sorry. ahead, Go

Maury Raycroft

the And then, much on study? larger scan just occupancy you and have established different or would those next step receptor or PET acceptable for do points to move time a you PET to scans in drug the a threshold to how multiple test individuals one be at

Barbara White

questions. great So

individuals. question those study. be or overweight a pharmacokinetics First, in testing, Phase individual. would There’s safety, about normal tolerability, that be is and parameters potential a X than they part different That of might obese the

So we will test that, dealing going lot obese be with because if people. we’re targeting NASH, of to we’re a

straightforward that safety a we need. early understanding that’s So PK and

way PET done, will they’ll first, been his we’ll we’ve move and working get Dr. and as the the be with doses these studies of from it is George obese there. those quite will XXXX scan at NIH. individuals. loaded colleagues be some the We closely with doing will move there. and We’ve The study patients got done, the After into multiple Kunos

is up CBX injected they a And will and light PET – brain. will that will then specific be their for we ligand, scanning with

see the before another their receive in that the have have know the a much ligand and first and – binding brain, there’s of ligand. So they displacement to anything, we’ll of get of if how study drug, they’ll we they’ll at see any then bonds baseline study the

not around events, that that days that be placebo. be are compared or suggests literature and and XXXX than that placebo, we the would a gets or see – The days, if in we’re to for cohort probably placebo results available ligand XXXX range seven are for the better in will gets likely displacement the the that studies for cohort of CNS So more in variability less than a and will levels whether displaces XX% look for that. binding specific the adverse data less seven

really in would – room think range would know, in would would the, we if less XX%, in think and about or a we think Certainly, for it. I you but certainly be XX% XX% saw be we comfortable be that no, and we little and range would specific between, that between, caution binding would think forward, we’ll interpret a need to move lot, bit I about, somewhere

Maury Raycroft

you And good. will start that study? in announce you very dosing when it, individuals Got

Barbara White

Tuesday. as and expect start it on announce we’ll and Sure I target we’re said, we in to

good. So far so

Maury Raycroft

okay. you very it, Got Thank much.

Operator

the next of Gershell Our proceed Oppenheimer. question with from your with Please is questions. line Leland

Leland Gershell

morning, Good Hi. everyone.

two-part part. you’re the that interfering work know Just lenabasum the used You actually conditions a byproducts question having which for its Thanks. that against – of as anti-inflammatory with or some kinds and to either can those very comment are to of are and lenabasum therapeutics on, of I other And at? know, used that second then that potentially go these and interfere wondering, given have mechanisms variety is which function Barbara often with you a relates versus of it agents drugs resolution? that well could looking

Barbara White

be So will think with efficacy question. And a safe might potential interactions I’m is, if there be drug-drug therapies? what’s – effects? or if may antagonist repeat synergistic the other that combination What in It take I I be that lenabasum signal. might to

that expression of on it and you the or as seen treatment, doing activated evidence their significant immune not of that, on really cetera. et studying in patients profile. are So CBX just is, background felt the today whatever abnormalities the been we that’s And not, always safety comfortable they’re when tests, away fact interactions drug-drug we cells clinical the because increases lab goes we’ve approach know,

as some we immunosuppressive is of we’ll that on trial patients know might in the the background be efficacy think over could MMF, when even such the see who better done. analyses I and are subset it’s obviously Mechanistically, possible

that But activating else absolutely of diseases. novel. for is treating provides This example, we This Nobody inflammation have the these chronic doing new and inflammatory is a approach is brand that. new. approach whole fibrotic resolution to of

mountain, So know the climb the the lenabasum the and a mechanisms, the a things if as turning perhaps you up hill climb activates you view disease that down the sort hill, going of down off. hill, that

are there the some Although certainly on effects phases. activation

you But even potential, you better efficacy. see things, might a if pair

don’t belief that, we’ll in to However, we we’ve concomitant that know find out way, it and itself. without we’re And and by I lenabasum that studies itself the no tested needs by immunosuppressives. have testing be current

every clinical expectation really have benefit. we will see We substantial that

that organ will with control, have and well think I certain So to be as monotherapy upon, disease that in will Craig can talk more, as think early we who preferences know, therapy, that patients about it the bring combination involvements active way early either used in patients you depending early the and under be physicians. it as

drug-drug significant we’ve of studies, modeling likes that potential consistent done FDA the with patients usually are of not Drug-drug that, some see. use. And interaction the the there some some they’re to types with compounds, interactions compounds while what

there. or still I commercially didn’t your Craig, you not views own know if combination. we’re in comment expecting if So you wanted about significant issues to of

Craig Millian

are significant you be some to immunosuppression profile the to expect without efficacy on said, incremental that Barbara based certainly opportunity adding the the will of with adding will compelling. adding we burden, add you as background but there’s adding sort most today, tolerability obviously know, overall safety And patients significant seen treatment know, Yeah. not we’ve on I very know, both, you think significant lenabasum data. and come while opportunity that the Certainly, down to certainly and for it

top lenabasum consider Certainly in the immunosuppressants. well of that de who’s there provider for patients disease well. further some problematic opportunity nice as may are drug newly try and there to down obviously and a experience as for to want side of to the a patient immunosuppression effects that patient be amount titrate the would on diagnosed there even in terms also patients for and we is degree, it disease more their to mind the first have stable they who be would certainly certainly along opportunity Their first love diagnosed novo of healthcare

And oral, you diagnosed very safety are of treated tolerability obviously agent. the that lenabasum to it’s certainly would we our market strategy community and quite being profile potentially first rheumatologists know, by as again, be to-date the about patients and when think the going the we line that, you construct often go-to how about to and these think we insights – it the as looking reasonable. attractive And advocacy, being consider

So you covers it know, we really multiple think bases.

Leland Gershell

very just helpful. But quick a follow-up. that’s Thanks,

be CRISS through this As is mean really too just line in we endpoints, [indiscernible] if look you at towards point, just to limited of the indication the will to sclerosis, patient, or the Thanks. the we’re secondary RESOLVE it I can the readout you X subcomponents, more systemic give data? going see in top the the top breakdown line

Barbara White

it each provide could all the address would components the of benefit that primary. lenabasum if not – the that most, Definitely, you’ll see expect, We’ll the is CRISS, be individually how it’s because think you’ll CRISS reasonable the we’re to see to secondary, treating. of and of the totality on the I illness

you at it would and to the secondary. would, what overall in score I that like the look but I intent components this can’t I covers So, promise show our point, be think the

Leland Gershell

Great, thanks for questions. taking the much very

Operator

your proceed Bayko with question next Securities. Liisa the is of with Please line JMP Our questions. from

Unidentified Participant

importance biopsies taking at biomarkers. clinically guess think what you these between for Thanks on on and and Can patients? for a RESOLVE in the questions. of seeing [ph] following when you the [John] you’re changes I Hi, Liisa. up looking the previous seeing you’re discuss correlation how X, biomarker question, in

Barbara White

sure I expect some would not clinical would But had I – fabulously That’s strong it. certainly correlation. know, the forth think to it will so that’s so outcomes the because discussions as I’m a do You to and we correlation, see there’s see variability there there between, know, in difference And I certainly and to – I outcomes. be correlate. and we on. would you expect many why clinical expect skin

can drug support the have when of that we we this impact on you So look very at underlying that efficacy are outcomes pathogenesis. the sensible disease

Unidentified Participant

Thanks. And just more I guess Craig. for one

and targeting you’re kind Thanks. discussed your sales tiering on he those rheumatologists, your the discussed about size thoughts docs force? of You X,XXX then of how

Craig Millian

Sure. know you we lending mean who to you awareness itself a often know, be at centers take our diagnosis. rheumatologists so understanding I who would launch, be our those get know, profile, talked are immediately getting with is and are the patients, academic about, product you the going clearly goal treatment just as think back, both community rheumatologists Yeah, as treat know, and treating started we and and goal patients both well, to on community-based for to step diagnosing patients build those well scleroderma we excellence upon of are you the at that

So, you envision a commercial foremost we that field medical envision haven’t caveat of and customer-facing national being this sizing first formal duly excellence, know, roughly centers of a done we medical a as – would you ensuring know, well covered as but, we team. by the and coverage by a saying, let footprint, XX me team force sales yet, exercise would scleroderma

community-based to preliminarily preliminary rheumatologists that practice. We be XX in have but we those be that their the of is estimate And, – quite is and patients on X,XXX know, their using it, call to practice, right validate going we’re scleroderma now more to scleroderma additional to are treating would number and work you done a cutoff the or have And between this in also number capacity one patients number. sizable again, they rheumatologists. who X,XXX roughly there’s

sized specialty sales reach, mentioned, fairly a team. a then, but more team as innovative I approaches we expect and augment want medical of than with XX, would I modestly with and have field-based no national multichannel So obviously to marketing strong also that

Unidentified Participant

taking thanks congrats on the for Great, questions the and progress.

Barbara White

you. Thank

Craig Millian

you. Thank

Operator

concludes your in today. everyone. you, question-and-answer session conference Thank for Thank This participation. you for our

have your a disconnect now may day. and at lines You wonderful this time

Yuval Cohen

Take safe. everyone. you, Thank and stay care

Corbus Pharmaceuticals (CRBP) 12 Mar 202019 Q4 Earnings call transcript